New Delhi: In the absence of safety and efficacy data, the Ministry of Health has suggested not to use monoclonal and antivirus antibodies such as remedyivir, favipirailivir, molnupiravir and fluvoxamine in children less than 18 years old, regardless of the severity of infection.
These recommendations are part of the revised guidelines for managing Covid-19 among children and adolescents under 18 years.
Guidelines have been revised given the current surge surge which is powered by Omicron.
It also underlines that if the steroid is used, they must tap more than 10 to 14 days, subject to clinical improvement.
Data available from other countries show that diseases caused by omicron variants are less severe.
However, there is a need for observation because the wave is currently evolved, the new guide said.
They in the age group 0-19 years, accounted for 11% of cases and 0.7% of deaths in 2021, due to 18% of cases and 0.9% death by 2020, the government said.
Revised guidelines also suggest exercise be careful when diagnosing multi-system inflammatory syndrome (MIS-C).
“To diagnose mis-c, caution must be done while interpreting an isolated increase in covid antibodies,” he said.
Children who develop such syndrome after recovery from Covid-19 usually have symptoms such as repeated fever, rash, conjitival, diarrhea, vomiting and bleeding tendencies.
Don’t use Remdesivir, Molnupiravir to treat children under age: Government
